insulin glulisine vs THDB0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin glulisine · Apidra
Marketed by Sanofi
NCT00290927 · Phase 3 · completed
The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.
Reported efficacy
Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)
Result source: NCT00135057
THDB0206
Developed by Adocia and partners
NCT05834868 · Phase 3 · completed
The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin glulisine | THDB0206 |
|---|---|---|
| HbA1c, change | -0.5% vs -0.5%vs Insulin LisproNCT011942582 other results
| —Not posted · NCT05834868 |
| Body weight, change (kg) | 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
| —Not posted · NCT05834868 |
| HbA1c below 7% | 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
| —Not posted · NCT05834868 |
| Fasting plasma glucose, change | —Not posted · NCT00135057 | —Not posted · NCT05834868 |
| 3-point MACE (% with event) | —Not posted · NCT00135057 | —Not posted · NCT05834868 |
HbA1c, change
- insulin glulisine
- -0.5% vs -0.5%vs Insulin LisproNCT01194258
2 other results
- -2.5% vs -2.1% NCT00384085
- -0.4% vs -0.1% NCT00360698
- THDB0206
- —Not posted · NCT05834868
Body weight, change (kg)
- insulin glulisine
- 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 1.5 vs 1.6 NCT01194258
- THDB0206
- —Not posted · NCT05834868
HbA1c below 7%
- insulin glulisine
- 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 51.1% vs 39.5% NCT00384085
- THDB0206
- —Not posted · NCT05834868
Fasting plasma glucose, change
- insulin glulisine
- —Not posted · NCT00135057
- THDB0206
- —Not posted · NCT05834868
3-point MACE (% with event)
- insulin glulisine
- —Not posted · NCT00135057
- THDB0206
- —Not posted · NCT05834868
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
THDB0206: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. insulin glulisine: 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin glulisine |
|---|---|
| Dropout rate | 23.5%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 11.9%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 6.5%Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence 0%Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 3 more resultsany infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 11.9% diarrhoea 8.5% nasopharyngitis 5.1% NCT01194258 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin glulisine
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · THDB0206's landscape